Education
About Us
Working with TipRanks
Follow Us
Amgen (HK:4332)
:4332
Earnings Data
Report Date
Feb 03, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
37.61Last Year’s EPS
41.29Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call showcased strong financial performance with a 12% revenue increase and significant volume growth driven by key products. There were notable advances in cardiovascular studies and the biosimilar portfolio, alongside new initiatives like AmgenNow to improve patient access. However, the call also highlighted challenges such as increased competition in certain segments, generic impacts on rare disease products, and some delays in study readouts. Overall, the positives in growth and strategic initiatives outweighed the negatives.Company Guidance
Strong Revenue Growth
Revenues increased 12% year-over-year to $9.6 billion, driven by strong performance from key growth drivers like Repatha, EVENITY, TEZSPIRE, innovative oncology, rare disease, and biosimilar portfolios.
Record Volume Growth
Volume growth was up 14% year-over-year with 16 products achieving double-digit growth rates; 14 products are now annualizing at over $1 billion in sales.
Significant Advances in Cardiovascular Studies
The Repatha Phase III VESALIUS-CV study met its primary endpoints demonstrating significant reductions in major adverse cardiovascular events in high-risk individuals without prior heart attacks or strokes.
Biosimilar Growth
The biosimilar portfolio delivered a 52% increase in sales year-over-year, now annualizing at $3 billion.
Introduction of AmgenNow
AmgenNow initiative launched to provide direct-to-patient access for Repatha at reduced prices, significantly increasing accessibility for patients.
Debt Reduction and Financial Discipline
Successfully retired $6.0 billion of debt in 2025 and achieved pre-Horizon capital structure ahead of plan.
HK:4332 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HK:4332 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | HK$1761.00 | HK$1761.00 | 0.00% |
Aug 05, 2025 | HK$1742.40 | HK$1742.40 | 0.00% |
Feb 04, 2025 | HK$1705.87 | HK$1705.87 | 0.00% |
Oct 30, 2024 | HK$1688.90 | HK$1688.90 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amgen (HK:4332) report earnings?
Amgen (HK:4332) is schdueled to report earning on Feb 03, 2026, After Close (Confirmed).
What is Amgen (HK:4332) earnings time?
Amgen (HK:4332) earnings time is at Feb 03, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Amgen stock?
The P/E ratio of Amgen is N/A.
What is HK:4332 EPS forecast?
HK:4332 EPS forecast for the fiscal quarter 2025 (Q4) is 37.61.
